Ron Gutmark, MD
Ophthalmology · Glendora, CANPI 1609189893
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Amgen at 35.5% of the total. 2025 is the largest year on record at $1,728, 5.5 times the $316 reported in 2019.
Across 176 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Alcon$535
- Sun Pharmaceutical Industries Inc.$532
- Bausch & Lomb Americas Inc.$340
- Oyster Point Pharma, Inc.$281
- Dompe US, Inc.$154
- plus $606 from 12 others
Across 66 payments — averaging $1821.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$111K
- Glaukos Corporation$9K
What the payments were for
- Food & beverage$3,795100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 83 | $1,346 |
| Alcon | 22 | $535 |
| Sun Pharmaceutical Industries Inc. | 17 | $532 |
| Bausch & Lomb Americas Inc. | 4 | $340 |
| Oyster Point Pharma, Inc. | 15 | $281 |
| Dompe US, Inc. | 6 | $154 |
| Tarsus Pharmaceuticals, Inc. | 4 | $107 |
| AbbVie | 6 | $101 |
| Thea Pharma Inc. | 4 | $89 |
| Rxsight Inc | 3 | $75 |
| Aerie Pharmaceuticals, Inc. | 2 | $47 |
| Ivantis, Inc | 2 | $38 |
| Harrow Eye, LLC | 1 | $29 |
| Sight Sciences, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $28 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $28 |
| Shire North American Group Inc | 1 | $22 |
| Glaukos Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$229
- AMVISC$229
How this compares
$3,795 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 82 | $76,333 |
| CequaCyclosporine | 110 | $69,045 |
| LumiganBimatoprost | 66 | $33,218 |
| Cyclosporine | 65 | $25,227 |
| XiidraLifitegrast | 29 | $24,279 |
| TyrvayaVarenicline Tartrate | 33 | $22,548 |
| RocklatanNetarsudil Mesylat/Latanoprost | 50 | $20,283 |
| MieboPerfluorohexyloctane/Pf | 12 | $15,417 |
| Prednisolone Acetate | 299 | $9,822 |
| ProlensaBromfenac Sodium | 27 | $9,302 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $8,245 |
| RhopressaNetarsudil Mesylate | 17 | $7,550 |
| Alphagan PBrimonidine Tartrate | 15 | $6,930 |
| MoxifloxacinMoxifloxacin Hcl | 242 | $6,565 |
| Latanoprost | 674 | $6,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $101 | $124,726200 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $532 | $69,045110 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $340 | $45,37157 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $47 | $27,83367 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $281 | $22,54833 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $28 | $9,30227 claims |
| AlconSimbrinza | $535 | $4,45821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Glendora
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.